Market Closed -
Hong Kong S.E.
04:08:20 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
6.47
HKD
|
+7.83%
|
|
+8.92%
|
-3.14%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
13,433
|
9,507
|
5,967
|
4,154
|
4,154
|
-
|
Enterprise Value (EV)
1 |
11,382
|
7,733
|
4,682
|
4,193
|
3,217
|
3,186
|
P/E ratio
|
-
|
-33.2
x
|
-13.5
x
|
-10.3
x
|
-16.6
x
|
-79.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,026
x
|
169
x
|
37.5
x
|
17
x
|
9.37
x
|
5.14
x
|
EV / Revenue
|
869
x
|
138
x
|
29.5
x
|
17
x
|
7.25
x
|
3.94
x
|
EV / EBITDA
|
-25.5
x
|
-20.1
x
|
-10.4
x
|
-10.7
x
|
-26.1
x
|
-71.2
x
|
EV / FCF
|
-
|
-8.97
x
|
-14.8
x
|
-14.8
x
|
14.8
x
|
33.5
x
|
FCF Yield
|
-
|
-11.1%
|
-6.76%
|
-6.73%
|
6.78%
|
2.98%
|
Price to Book
|
5.37
x
|
2.79
x
|
2.17
x
|
1.74
x
|
1.55
x
|
1.78
x
|
Nbr of stocks (in thousands)
|
591,140
|
666,743
|
688,737
|
693,655
|
693,655
|
-
|
Reference price
2 |
22.72
|
14.26
|
8.664
|
5.989
|
5.989
|
5.989
|
Announcement Date
|
3/19/21
|
3/25/22
|
3/30/23
|
3/21/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
13.1
|
56.15
|
159
|
246.4
|
443.6
|
809
|
EBITDA
1 |
-447.1
|
-383.9
|
-452.3
|
-393.1
|
-123.4
|
-44.74
|
EBIT
1 |
-451.7
|
-385.9
|
-455.9
|
-402.1
|
-253.5
|
-134
|
Operating Margin
|
-3,449.28%
|
-687.36%
|
-286.78%
|
-163.23%
|
-57.15%
|
-16.57%
|
Earnings before Tax (EBT)
1 |
-
|
-260
|
-402.2
|
-379.5
|
-250.4
|
-53.51
|
Net income
1 |
-
|
-260
|
-402.6
|
-379.8
|
-250.9
|
-3.016
|
Net margin
|
-
|
-463.06%
|
-253.3%
|
-154.15%
|
-56.57%
|
-0.37%
|
EPS
2 |
-
|
-0.4300
|
-0.6400
|
-0.5900
|
-0.3600
|
-0.0750
|
Free Cash Flow
1 |
-
|
-861.7
|
-316.5
|
-215
|
218
|
95
|
FCF margin
|
-
|
-1,534.67%
|
-199.09%
|
-82.44%
|
49.14%
|
11.74%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/21
|
3/25/22
|
3/30/23
|
3/21/24
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
---|
Net sales
1 |
-
|
11.14
|
20.8
|
35.34
|
54.54
|
104.4
|
103.7
|
142.7
|
169.5
|
259.7
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-
|
-179.7
|
-206.2
|
-218.5
|
-237.4
|
-224.9
|
-177.3
|
-152.3
|
-132.8
|
Operating Margin
|
-
|
-
|
-863.94%
|
-583.43%
|
-400.68%
|
-227.3%
|
-216.86%
|
-124.26%
|
-89.82%
|
-51.12%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-1,742
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-27.00
|
-
|
-
|
-
|
-0.3100
|
-0.3300
|
-0.3200
|
-0.2700
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/26/20
|
3/19/21
|
8/20/21
|
3/25/22
|
8/26/22
|
3/30/23
|
8/24/23
|
3/21/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,052
|
1,774
|
1,285
|
962
|
937
|
969
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-862
|
-316
|
-215
|
218
|
95
|
ROE (net income / shareholders' equity)
|
-128%
|
-9.27%
|
-13.7%
|
-14.3%
|
-8.4%
|
-7.41%
|
ROA (Net income/ Total Assets)
|
-
|
-8.77%
|
-12.6%
|
-13.6%
|
-7%
|
-2.9%
|
Assets
1 |
-
|
2,965
|
3,187
|
3,120
|
3,585
|
104
|
Book Value Per Share
2 |
4.230
|
5.120
|
3.990
|
3.440
|
3.860
|
3.370
|
Cash Flow per Share
2 |
-
|
-0.3200
|
-0.3200
|
-0.1700
|
0.4200
|
0.3000
|
Capex
1 |
-
|
665
|
116
|
121
|
75
|
114
|
Capex / Sales
|
-
|
1,184.07%
|
72.86%
|
46.4%
|
16.91%
|
14.09%
|
Announcement Date
|
3/19/21
|
3/25/22
|
3/30/23
|
3/21/24
|
-
|
-
|
Last Close Price
5.989
CNY Average target price
7.77
CNY Spread / Average Target +29.74% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.14% | 573M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|